drugset / Trial / NCT00607152
Rasburicase (Fasturtec) Registration Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary: To compare the efficacy of Rasburicase versus allopurinol in controlling tumor lysis-related hyperuricemia in Chinese patients with leukemia or lymphoma. Secondary: To compare the efficacy and safety of Rasburicase versus allopurinol in Chinese patients stratified according to disease (leukemia or lymphoma ).
Timeline
- Start
- 2007-10
- Primary completion
- 2009-01
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Allopurinol | Small molecule | 100 mg | Oral |
| Subject | Rasburicase | Protein / enzyme biologic | 0.2 mg/kg | Intravenous |
Indications
No indication recorded.